Please login to the form below

Not currently logged in
Email:
Password:

GRI

This page shows the latest GRI news and features for those working in and with pharma, biotech and healthcare.

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Ziylo could help it stay ahead in key insulin franchise. Novo Nordisk is aiming to develop the world’s first glucose responsive insulin (GRI) by acquiring UK biotech start-up Ziylo.

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    TiGenix’ board is backing the takeover deal, which values the company at 520m (around $630m), and two major shareholders - Gri-Cel and Grifols - have already said they will tender their shares.

  • No man is an island

    Perhaps the most high-profile example of these is the Global Reporting Initiative (GRI), which now has 50 pharmaceutical and biotech companies among its 1, 000-plus registered organisations.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics